

Presidential symposium

Discussion about

PL03.03: Randomised Phase III study of osimertinib vs  
platinum-pemetrexed for *EGFR* T790M-positive advanced  
NSCLC (AURA3)

by

Vassiliki A Papadimitrakopoulou, Yi-Long Wu, Myung-Ju Ahn, Suresh S Ramalingam,  
Marina Chiara Garassino, Hye Ryun Kim, Frances A Shepherd, Hiroaki Akamatsu,  
Willemijn SME Theelen, Chee Khoo Lee, Martin Sebastian, Alison Templeton, Marcelo  
Marotti, Serban Ghiorghiu, and Tony Mok

Tetsuya Mitsudomi, MD, PhD


Department of Thoracic Surgery, Kindai University Faculty of Medicine,  
Osaka-Sayama 589-8511, Japan

## Disclosures

Tetsuya Mitsudomi, MD, PhD

- Grant/research support: AstraZeneca, Pfizer, Chugai, Taiho, and Boehringer Ingelheim.
- Advisory role: AstraZeneca, Pfizer, Chugai, Novartis, Boehringer Ingelheim, Kyowa Hakko-Kirin, MSD, and Clovis
- Honoraria: AstraZeneca, Pfizer, Chugai, Taiho, Boehringer Ingelheim, Ono pharm.
- Co-PI of AURA2


# Mechanisms of acquired resistance against EGFR-TKI



Camidge et al., Nature Rev Clin Oncol, 2014

# Clinical development of osimertinib

2011.6  
first synthesis of osimertinib




**AURA Phase I**  
EGFR-TKI failure  
Dose escalation/dose expansion PE safety and tolerability

**EXTENSION phase II**  
T790M + ≥ 2L PE

**AURA2 Phase II**  
-T790M + ≥ 2L PE  
ORR

**AURA 3** Phase III; Osimertinib vs Pt/Pem  
T790M+, 2L, PE, PFS

**FLAURA** phase III vs Pt/Pem



Modified from Yver, Ann Oncol 27: 1165–1170, 2016

以上内容仅为本文档的试下载部分，为可阅读页数的一半内容。如要下载或阅读全文，请访问：<https://d.book118.com/085304141343011224>